I guess with InterMune's drop in market cap expanding his focus to Alzheimer's and AMD gives more hype room. I have a suspicion there is no IPF program in the works (perhaps if they get *free funding*) as he seems to paraphrase InterMune's latest presentation (though he often misspeaks such as saying InterMune has an SPA-they do not to my knowledge). The latest is talking about a 72 week study (gee what a coincidence earlier this year InterMune expanded their study to 72 weeks).
If you really want a kick dig up the photo of Kanzer after the ODAC meeting for DOR. Someone posted it on the Pipex board and I believe I posted a link to the persons post.
For something not so funny one could ready the SEC filing:
On October 31, 2006, the non-interest bearing loans payable to the Company’s founder, Chairman and Chief Executive Officer, which amounted to $3,274,728, were converted into 4,995,633 shares of common stock and 2,497,817 warrants to purchase common stock. (See Note 5(D))
In addition, as part of the private placements, the Company issued warrants to purchase 2,874,831 shares of common stock to the placement agent, which is a company that is controlled by the Company’s Chairman and CEO. The warrants have an exercise price of $0.74. [they’ve had a 3-1 reverse split since then]
Market Data 
Markets 
AI
